These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 38143370)

  • 1. Prevalence of Concomitant Pathologies in Parkinson's Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms.
    Walker L; Attems J
    J Parkinsons Dis; 2024; 14(1):35-52. PubMed ID: 38143370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
    Robinson JL; Lee EB; Xie SX; Rennert L; Suh E; Bredenberg C; Caswell C; Van Deerlin VM; Yan N; Yousef A; Hurtig HI; Siderowf A; Grossman M; McMillan CT; Miller B; Duda JE; Irwin DJ; Wolk D; Elman L; McCluskey L; Chen-Plotkin A; Weintraub D; Arnold SE; Brettschneider J; Lee VM; Trojanowski JQ
    Brain; 2018 Jul; 141(7):2181-2193. PubMed ID: 29878075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
    Sierra M; Gelpi E; Martí MJ; Compta Y
    Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.
    Irwin DJ; Lee VM; Trojanowski JQ
    Nat Rev Neurosci; 2013 Sep; 14(9):626-36. PubMed ID: 23900411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology.
    de Pablo-Fernández E; Courtney R; Rockliffe A; Gentleman S; Holton JL; Warner TT
    Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1080-1091. PubMed ID: 33969516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
    Compta Y; Parkkinen L; O'Sullivan SS; Vandrovcova J; Holton JL; Collins C; Lashley T; Kallis C; Williams DR; de Silva R; Lees AJ; Revesz T
    Brain; 2011 May; 134(Pt 5):1493-1505. PubMed ID: 21596773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
    Sengupta U; Kayed R
    Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia.
    Chiu PY; Yang FC; Chiu MJ; Lin WC; Lu CH; Yang SY
    Sci Rep; 2022 Oct; 12(1):17919. PubMed ID: 36289355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies.
    Smith C; Malek N; Grosset K; Cullen B; Gentleman S; Grosset DG
    J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1234-1243. PubMed ID: 31444276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia.
    Compta Y; Parkkinen L; Kempster P; Selikhova M; Lashley T; Holton JL; Lees AJ; Revesz T
    Neurodegener Dis; 2014; 13(2-3):154-6. PubMed ID: 24028925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional Overlap of Pathologies in Lewy Body Disorders.
    Colom-Cadena M; Grau-Rivera O; Planellas L; Cerquera C; Morenas E; Helgueta S; Muñoz L; Kulisevsky J; Martí MJ; Tolosa E; Clarimon J; Lleó A; Gelpi E
    J Neuropathol Exp Neurol; 2017 Mar; 76(3):216-224. PubMed ID: 28395086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant Overlap of α-Synuclein, Amyloid-β, and Phospho-Tau Pathologies in Neuropathological Diagnosis of Lewy-related Pathology: Evidence from China Human Brain Bank.
    Cong C; Zhang W; Qian X; Qiu W; Ma C
    J Alzheimers Dis; 2021; 80(1):447-458. PubMed ID: 33554920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies?
    Kurosinski P; Guggisberg M; Götz J
    Trends Mol Med; 2002 Jan; 8(1):3-5. PubMed ID: 11796255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.
    Clinton LK; Blurton-Jones M; Myczek K; Trojanowski JQ; LaFerla FM
    J Neurosci; 2010 May; 30(21):7281-9. PubMed ID: 20505094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease.
    Blommer J; Pitcher T; Mustapic M; Eren E; Yao PJ; Vreones MP; Pucha KA; Dalrymple-Alford J; Shoorangiz R; Meissner WG; Anderson T; Kapogiannis D
    Brain; 2023 Jan; 146(1):195-208. PubMed ID: 35833836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology.
    Bassil F; Brown HJ; Pattabhiraman S; Iwasyk JE; Maghames CM; Meymand ES; Cox TO; Riddle DM; Zhang B; Trojanowski JQ; Lee VM
    Neuron; 2020 Jan; 105(2):260-275.e6. PubMed ID: 31759806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders.
    Irwin DJ; Hurtig HI
    J Alzheimers Dis Parkinsonism; 2018; 8(4):. PubMed ID: 30473927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.
    Ho CY; Troncoso JC; Knox D; Stark W; Eberhart CG
    Brain Pathol; 2014 Jan; 24(1):25-32. PubMed ID: 23714377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.